This web page was created programmatically, to learn the article in its unique location you'll be able to go to the hyperlink bellow: https://www.medrxiv.org/content/10.64898/2026.06.16.26355748v1and if you wish to take away this text from our web site please contact us [ad_1] AbstractBackground: It stays unclear why biomarker-defined Alzheimers illness neuropathological change (ADNC) results in cognitive decline and dementia in some people however not others. Multidomain way of life profiles could affect each pathology threat and medical expression. Objectives: To decide whether or not multidomain way of life profiles are related to (1) the danger of biomarker-defined ADNC and (2) the medical expression of AD pathology, together with longitudinal cognitive check rating change and incident dementia. Design/Setting: Retrospective longitudinal population-based cohort examine throughout the Trondelag Health Study (HUNT), Norway, together with 5 waves over a 40-year follow-up interval. Participants: The late-life supply inhabitants includes 9,956 HUNT4 70+ members, of whom 5,729 participated within the Ageing in Trondelag (AiT) follow-up. Outcome measurements. ADNC is operationalized primarily utilizing plasma phosphorylated tau at threonine 217 (p-tau217), with plasma neurofilament mild (NfL) obtainable as a complementary marker of neurodegeneration. In HUNT4 70+, members aged 70 and older had a standardized cognitive diagnostic evaluation, which was repeated at AiT 4 years later. Lifestyle Measurements: Multidomain way of life will probably be outlined throughout 5 domains: vitamin, bodily exercise and skeletal muscle well being, psychological and social well being, cardiovascular/metabolic standing, and cognitive stimulation. Genetic susceptibility, together with APOE and genome-wide/polygenic threat measures, and obtainable multi-omics knowledge will probably be examined as modifiers. Results: Analyses will look at the associations of multidomain way of life profiles and domain-specific exposures with each ADNC threat and medical expression. Conclusions: This examine will check whether or not multidomain way of life profiles are related to each the danger of biomarker-defined ADNC and the medical expression, informing threat stratification and modifiable prevention in AD.Competing Interest StatementHolger Frohlich experiences help for the current manuscript and grants/contracts from the Innovative Health Initiative, paid to the Fraunhofer Society. Miia Kivipelto experiences grants or contracts from the Academy of Finland, Swedish Research Council, Alzheimers Research and Prevention Foundation, EU seventh Framework Programme, CIMED, JPND, IMI, Wallenberg Clinical Grant, FORTE, KI-Janssen Strategic Collaboration, Imperial College ITMAT, Innovative Health Initiative, Gates Ventures, ADDI, Alzheimers Drug Discovery Foundation, and Part the Cloud; fee or honoraria from Eisai, Eli Lilly, Novo Nordisk, and Nutricia; participation on advisory boards for BioArctic, Combinostics, Eisai, Eli Lilly, Nestle, and Roche; and management or fiduciary roles with the Board of Governors of the Alzheimers Drug Discovery Foundation and the World Dementia Council. Mark van der Giezen experiences help for the current manuscript and grants/contracts from the Innovative Health Initiative, paid to Stavanger University Hospital. Audun Osland Vik-Mo experiences help for the current manuscript from Helse Stavanger/University of Bergen and advisory board membership for Eisai. Antoine Leuzy is Founder and CEO of ZRO Imaging. Ole A. Andreassen experiences institutional help or grants from the Research Council of Norway, NordForsk, NIH, EU, KG Jebsen, Novo Nordisk, and the South-Eastern Norway Regional Health Authority; royalties from a psychiatry textbook; consulting charges from Cortechs.ai and Ledidi AS; honoraria from Lundbeck, Eli Lilly, BMS, Medice, Janssen, Otsuka, and Sunovion; advisory board participation for Ledidi; a management or fiduciary position with the Research Council of Norway; and inventory or inventory choices in Cortechs, Ledidi, and Precision Health. Geir Selbaek has participated in advisory board conferences for Eli Lilly and Eisai relating to disease-modifying medication for Alzheimers illness, and has obtained honoraria for lectures at symposia sponsored by Eisai and Eli Lilly. Dag Aarsland has obtained analysis help and/or honoraria from Evonik, Roche Diagnostics, GE Health, and Sanofi, and has served as a paid advisor for Eisai, BioArctic, Eli Lilly, Enterin, Roche Diagnostics, Acadia, GSK, EIP Pharma, Biogen, Takeda, Zylvan, and Discoveric Alpha Consulting. The remaining authors declare no conflicts of curiosity. Acknowledgment The Trondelag Health Study (HUNT) is a collaboration between HUNT Research Centre, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondelag County Council, Central Norway Regional Health Authority, and the Norwegian Institute of Public Health. We thank the inhabitants of Trondelag for his or her willingness to contribute necessary knowledge and organic materials, and the workers at HUNT Research Centre and collaborating establishments for his or her contributions to the planning, assortment, storage, and administration of HUNT knowledge and organic materials. The Norwegian National Centre for Ageing and Health contributed to the funding of the HUNT4 70+ survey and funded the Ageing in Trondelag (AiT) examine. The HUNT4 70+ survey obtained extra funding from the Center for Oral Health Services and Research, Trondheim. The genetic investigations of the HUNT Study are a collaboration between researchers from the Okay.G. Jebsen Center for Genetic Epidemiology, NTNU, and the University of Michigan, with SNP genotyping carried out by the Genomics Core Facility at NTNU. Funding This work is supported by ACCESS-AD, inner help from the Centre for Age-Related Medicine (SESAM), and in-kind contributions from PhD candidates, postdoctoral researchers, and principal investigators. Author DeclarationsI affirm all related moral tips have been adopted, and any obligatory IRB and/or ethics committee approvals have been obtained.YesI affirm that each one obligatory affected person/participant consent has been obtained and the suitable institutional types have been archived, and that any affected person/participant/pattern identifiers included weren't identified to anybody (e.g., hospital workers, sufferers or members themselves) outdoors the analysis group so can't be used to determine people.YesI perceive that each one medical trials and another potential interventional research have to be registered with an ICMJE-approved registry, corresponding to ClinicalTrials.gov. I affirm that any such examine reported within the manuscript has been registered and the trial registration ID is supplied (word: if posting a potential examine registered retrospectively, please present a press release within the trial ID area explaining why the examine was not registered upfront).Yes I've adopted all acceptable analysis reporting tips, corresponding to any related EQUATOR Network analysis reporting guidelines(s) and different pertinent materials, if relevant.YesData AvailabilityApplications for entry to HUNT Databank knowledge will probably be submitted in accordance with procedures established by the HUNT Research Centre and the Norwegian University of Science and Technology (NTNU). The software will embrace an in depth mission description, examine goals, requested variables, knowledge administration plan, and related moral approvals. Data entry will probably be contingent on approval from the related moral and knowledge safety authorities and the HUNT Data Access Committee. All analyses will adjust to relevant laws for privateness, knowledge safety, and accountable dealing with of delicate well being data.Funder Information DeclaredThis work is supported by ACCESS-AD, inner help from the Centre for Age-Related Medicine (SESAM), and in-kind contributions from PhD candidates, postdoctoral researchers, and principal investigators. [ad_2] This web page was created programmatically, to learn the article in its unique location you'll be able to go to the hyperlink bellow: https://www.medrxiv.org/content/10.64898/2026.06.16.26355748v1and if you wish to take away this text from our web site please contact us